Zhong Nanshan talked about the new championship and attracted attention; Xiangya's evil medical treatment was suspended; the sky -high medicine was 20 million

This week, the new crown epidemic has continued in Hainan and other places.

According to data from the National Health and Health Commission, as of August 20, there were 8,449 confirmed cases across the country, and 553 cases of local diagnosis were added on the 20th. In the local area, Hainan Province reported on the 21st that the province's epidemic situation declined significantly, and the number of new infections "decreased by more than 27%for two consecutive days.

At the policy level, various policies are densely introduced. The National Medical Insurance Bureau launched the prices of medical services and consumables for oral termination; the National Health and Health Commission jointly issued a document to request maternity support measures;

In terms of market, the "sky -high price" transaction continues: Genting Xinyao transferred an ADC introduced to Geely, with a total of 3.067 billion yuan in total; Merhado reached a cooperation with ORNA Therapeutics, betting the ring, bet on the ring RNA therapy.

In terms of new drugs, another "most expensive medicine in history" was approved for listing. On August 17, the Blue Bird Bio, a head company in the United States, announced that the FDA approved that it was listed on gene therapy for the treatment of beta thalassemia at a price of 2.8 million US dollars.

More hot spots are organized as follows:

Heavy policy

1. The State Medical Insurance Administration solicited opinions on dental implants charges

On August 18, the official WeChat of the National Medical Insurance Bureau issued the "Notice on the Development of Oral Planting Medical Service Charges and Special Governance of Consumption (Draft for Soliciting Opinions)".

The "Notice" regulates four major items and 12 small items including oral planting medical services and consumables charging methods. It is worth noting that the National Medical Insurance Administration requires that the proportion of prices in the entire dental process of implant surgery and crown surgery needs to be controlled at about 60%, and the price involved in the price is 10%. Highlight the "technical labor value".

On the issue of dental implants consumables, the State Medical Insurance Bureau requires that the total number of public and private medical institutions involved in collecting and mining must account for more than 40%of the number of local dental medical institutions.

2. Beijing Medical Insurance Workers' Clinic will no longer have a top -top line

On August 19, the Beijing Municipal Medical Insurance Bureau issued the "Notice on Adjusting the Related Policy of the Urban Workers' Basic Medical Insurance in the Municipality" stated: Since September, personal medical insurance accounts have achieved targeted use and cannot be withdrawn, but they will be issued before September 1st to arrive in the account. The funds inside the medical preservation can still be withdrawn normally. In addition, since next year, there will be no closure lines for the treatment of employees in Beijing.

At present, the maximum payment limit of the Beijing -employee medical insurance insured persons and the emergency department within a year is 20,000 yuan, which is more than 20,000 yuan.

3. The Ministry of Human Resources and Social Affairs issued a document: It is strictly forbidden to discriminate against the rehabilitation of new crown pneumonia

Recently, the news of the rejection of new crown pneumonians has repeatedly attracted attention on the Internet.

On August 16th, the Ministry of Human Resources and Social Security and the Supreme People's Court officially issued the "Notice on Strengthening the Equal Employment Rights of Equal Employment Rights of Equal Employment in Administrative Judicial Links to Increase Administrative Judicial License and Protecting the Rehabilitation of New Crown Pneumonia." "Waiting for the workers" should not be tested on the grounds that the new crown nucleic acid test was positive.

Industry affairs

1. Zhong Nanshan: No medicines can prevent new crowns at present

According to Guangming.com, at the 18th International Conference on August 20, Zhong Nanshan, an academician of the Chinese Academy of Engineering, said that as of now, no drug has been "able to prevent new crown pneumonia."

The Jianzhi Bureau learned that the development of new crown pneumonia prevention medication has become the idea of ​​some companies today. In May of this year, a 3CL protease inhibitor of Xianmin Pharmaceutical was approved by the clinical clinic for exposure prevention treatment of the new crowd -positive crowd; in early August, Han Yu Pharmaceutical said in response to investors' questions that the nose and pharynx spray spray New crown products such as doses such as doses may have a certain clinical value for preventing indications.

2. Liu Xiangfeng, a doctor of Xiangya Second Hospital, was removed from office

On August 17, the news of "Liu Xiangfeng, a doctor of Xiangya Second Hospital, there was a problem with medical style problems" attracted widespread attention on the Internet. Some netizens broke the news that the doctor not only received a large amount of gray income, but also had irregular diagnosis and treatment problems, such as frequent robot surgery of emergency patients, hundreds of thousands of high treatment to patients with no surgery, and "whether it was no matter not or not or not Tumors are treated by tumor. "

On August 18, Xiangya Second Hospital of Central South University issued a statement saying that Liu Xiangfeng did "have irregular behaviors" in the medical process. Surgical permissions. Relevant investigations are still continuing and will be announced to the society in time.

3. The founder

On August 17, according to interface news reports, Kingsuri sued Fan Xiaoli, the former founder of the legendary creature of the subsidiary on the grounds of "intellectual property dispute".

The Jianzhi Bureau noticed that on August 8th, a case of "violating business secrets" in Kingsuri was tried in the Nanjing Intermediate People's Court in Nanjing, Jiangsu Province. The defendant was named "Fanxiaohu". The case will be tried again in the Nanjing Intermediate People's Court on August 26.

Fan Xiaohu is one of the founders of the legendary creature and the first inventor of the domestic self-developed CAR-T Sidaki Olun. The legendary creature has previously relied on this product to start in the industry. However, at the end of March this year, Fan Xiaohu resigned from the legendary creature after being approved by the FDA for the listing of FDA. Sidam Olun is priced at US $ 465,000 per point in the United States. In July of this year, data disclosed by Kings Rui showed that the first quarter after the product was listed was $ 24 million.

New drug inventory

1. FDA approved the first innovative depression drug in 60 years

On August 20, AxSome Therapeutics, a listed company in Nasdaq, announced that the US FDA has approved a product called Auvelity for the treatment of depression adult patients. It is worth mentioning that Auvelity is the first depression oral therapy approved by the FDA in the past 60 years.

Auvelity is an innovative oral NMDA receptor antagonist, which contains two components: follow of Merrisfen and amponeone. A phase III clinical shows that compared with placebo, the relevant symptoms of depression patients treated with Auvelity have been significantly improved in the 6th week.

2. Sinopharm Group: Omikon MRNA vaccine submits clinical clinical

On August 15th, Zhu Jingjin, secretary of the China Biological Party Committee of the Chinese Medicine Group, said at the media exchange meeting that at present, the exterior vaccine of the Omikon mutation in China and the second -generation reorganized protein new crown vaccine has been clinically applied. Mutant MRNA vaccine has also submitted clinical applications.

Zhu Jingjin said that Chinese creatures "have been tracking the situation of global mutant plants and developed new vaccines in a targeted manner." The company noticed that new variable strains other than BA.4 and BA.5 have appeared in China. The targeted and comprehensive effects of vaccines are significant.

3. Sky price medicine for rare diseases, priced at 2.8 million US dollars

On August 17, the US FDA officially approved the concept of gene therapy company Bluebird Biological ZyNTEGLO gene therapy, becoming the world's first gene therapy to treat β-thalassemia. FDA said that in the relevant clinical trials, 89%of patients receiving ZyNTEGLO treatment have no need to receive regular blood transfusion treatment and do not have any obvious safety issues.

It is worth mentioning that ZyNTEGLO's pricing in the United States is as high as $ 2.8 million, which is more expensive than Nuohua's gene therapy Zolgensma, which is used to treat spinal muscle atrophy, has become the most expensive drug in the world.

####

- END -